Bionyra Pharma Raises $165M to Advance Next-Generation Immune Disease Treatments

Bionyra Pharma raised $165 million in an oversubscribed Series A round co-led by Jeito Capital and Sofinnova Partners. The clinical-stage biotech is advancing three antibody therapies targeting inflammatory bowel disease and atopic dermatitis. Lead candidate BYN-002, a TL1A monoclonal antibody, is in a fully enrolled Phase 1 study.